Anti-tumor effect enhancer and anti-tumor preparation

An anti-tumor agent and anti-tumor technology, applied in the direction of anti-tumor drugs, active ingredients of heterocyclic compounds, drug combinations, etc., to achieve a strong anti-tumor enhancement effect

Inactive Publication Date: 2015-03-25
朱忠良
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the antitumor effect of the combination therapy of liposome preparation and combination drug needs to be further improved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor effect enhancer and anti-tumor preparation
  • Anti-tumor effect enhancer and anti-tumor preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] DPPC (L-α-dipalmitoylphosphatidylcholine, CoatsomeMC-6060, manufactured by NOF Corporation), cholesterol (special grade, manufactured by Wako Pure Chemical Industries, Ltd.) and mPEG2000-DSPE (1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-n-[methoxy (polyethylene glycol)-2000], SunbrightDSPE-020CN, manufactured by NOF Company) was dissolved in chloroform to obtain 20mM, 50mM respectively and a concentration of 5mM. Subsequently, 5 ml of 20 mM DPPC solution, 0.5 ml of 50 mM cholesterol solution, and 1 ml of 5 mM mPEG2000-DSPE solution were placed in a pear-shaped bottle. While depressurizing using an evaporator, remove chloroform to form a lipid film at the bottom of the pear-shaped flask. The lipid film was dissolved with 6ml of chloroform / diethyl ether (volume ratio 1:2). Lomustine was dissolved in a 5% glucose solution so that the concentration of lomustine became 8 mg / ml. The lomustine solution (2 ml) thus prepared was added to the lipid solution, followed by ...

Embodiment 2

[0088]HSPC (hydrogenated soybean phosphatidylcholine, CoatsomeNC-21, manufactured by NOF Corporation), cholesterol (special grade, manufactured by Wako Pure Chemical Industries, Ltd.) and mPEG2000-DSPE (1,2-dihard Fatty acyl-sn-glycerol-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000], Sunbright DSPE-020CN, manufactured by NOF Company) was dissolved in chloroform to obtain concentrations of 20 mM, 50 mM and 5 mM, respectively . Subsequently, 5 ml of 20 mM HSPC solution, 1 ml of 50 mM cholesterol solution, and 2 ml of 5 mM mPEG2000-DSPE solution were placed in a pear-shaped bottle. While depressurizing using an evaporator, chloroform was removed to form a lipid film at the bottom of the pear-shaped flask. The lipid film was dissolved with 6ml of chloroform / diethyl ether (volume ratio 1:2). Lomustine was dissolved in a 5% glucose solution so that the concentration of lomustine became 8 mg / ml. The lomustine solution (2 ml) thus prepared was added to the lipid soluti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
phase transition temperatureaaaaaaaaaa
phase transition temperatureaaaaaaaaaa
Login to view more

Abstract

The invention relates to an anti-tumor effect enhancer and an anti-tumor preparation. The anti-tumor effect enhancer is a lipidosome preparation containing an effective dose of lumostine, and can be used for improving the anti-tumor activity of a combined medicine containing effective doses of tegafur, gimeracil and oteracil potassium. Compared with the prior art, the anti-tumor effect enhancer has the advantage of stronger anti-tumor enhancing effect for the combined medicine containing tegafur, gimeracil and oteracil potassium.

Description

technical field [0001] The invention relates to the technical field of anti-tumor drugs, in particular to an anti-tumor effect enhancer containing lomustine liposome preparation, and an anti-tumor agent containing the liposome preparation. Background technique [0002] So far, many anticancer agents have been developed and used in the medical field. For example, tegafur is activated in vivo and gradually releases the active form, ie, 5-fluorouracil (hereinafter referred to as "5-FU"), thus alleviating the toxicity or side effects exhibited by 5-FU. A combination drug containing tegafur, gimeracil, and oteracil potassium (trade name: TS-1, the molar ratio of tegafur / gimeracil / oxonate potassium =1:0.4:1, manufactured by Taiho Pharmaceutical Co., Ltd., hereinafter the combination drug is referred to as TS-1) has a stronger antitumor effect because gimerast inhibits 5 - Degradation of FU. In this formulation, the therapeutic effect is improved because oxonate potassium specif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/53A61K31/513A61K31/4412A61K31/44A61K9/127A61P35/00A61K31/175
Inventor 朱忠良
Owner 朱忠良
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap